Latest News

  • MARKET TRENDS

    2 Sep 2025

    First Generic GLP-1 for Weight Loss Sparks New Battle in US Market

  • PARTNERSHIPS

    29 Aug 2025

    Novo Nordisk Bets $550M on RNA's Next Act

  • TECHNOLOGY

    21 Aug 2025

    AI Joins the Fight Against Obesity

  • REGULATORY

    17 Aug 2025

    Conditional FDA Approval Puts Wegovy on Watch

The Next Obesity Breakthrough Could Be Written in Code

The Next Obesity Breakthrough Could Be Written in Code

INSIGHTS

14 Aug 2025

Eli Lilly partners with Superluminal to tap Al for faster obesity drug discovery beyond injectables.

First Generic GLP-1 for Weight Loss Sparks New Battle in US Market

MARKET TRENDS

2 Sep 2025

First Generic GLP-1 for Weight Loss Sparks New Battle in US Market

Teva's launch of a Saxenda copy shakes up pricing power, forcing Novo and Lilly to rethink access and affordability.

Novo Nordisk Bets $550M on RNA's Next Act

PARTNERSHIPS

29 Aug 2025

Novo Nordisk Bets $550M on RNA's Next Act

Novo Nordisk partners with Replicate Bioscience to develop RNA-based obesity therapies, aiming to evolve beyond current GLP-1 blockbusters...

AI Joins the Fight Against Obesity

TECHNOLOGY

21 Aug 2025

AI Joins the Fight Against Obesity

FDA clears Dexcom and Signos tools as insurers and clinicians weigh digital alternatives to costly weight-loss drugs

Conditional FDA Approval Puts Wegovy on Watch

REGULATORY

17 Aug 2025

Conditional FDA Approval Puts Wegovy on Watch

US regulator clears Novo Nordisk drug for MASH, but continued approval to depend on long-term trial data

The Next Obesity Breakthrough Could Be Written in Code

INSIGHTS

14 Aug 2025

The Next Obesity Breakthrough Could Be Written in Code

Eli Lilly partners with Superluminal to tap Al for faster obesity drug discovery beyond injectables.

Structure Extends Runway to 2027 Ahead of Key 2025 Data

INVESTMENT

7 Aug 2025

Structure Extends Runway to 2027 Ahead of Key 2025 Data

Structure raised $300M to advance its oral GLP-1 pill, with key data due in 2025 and cash runway into 2027.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.